BROOMFIELD, Colo., Oct. 14, 2011 /PRNewswire/ -- Data presented at the 10th International Kidney Cancer Symposium being held in Chicago, IL show that the pretreatment blood-based test, VeriStrat, was able to stratify renal cell carcinoma (RCC) patients treated with a combination of two targeted therapies, sunitinib (Sutent®) and erlotinib (Tarceva®), by survival outcomes. Patients who tested VeriStrat Good had significantly longer progression free survival (PFS) and overall survival (OS) when treated with the combination therapy as compared to patients who tested VeriStrat Poor.
The study retrospectively, and in a fully blinded fashion, applied the VeriStrat test to a subset of the patient population from a Phase I/II clinical trial of erlotinib plus sunitinib in RCC patients. VeriStrat analysis was performed on all available serum samples. Thirty-seven of 46 patients were classified as either VeriStrat Good or VeriStrat Poor based on the VeriStrat algorithm developed for non-small cell lung cancer (NSCLC).
The analysis showed that VeriStrat Good patients had a significantly longer PFS and OS versus VeriStrat Poor patients (PFS: median 12.3 vs. 4.7 months, log-rank p=0.025 and OS: median 38.4 vs. 11.6 months, log-rank p=0.045). There was a statistically significant correlation between VeriStrat classification and Heng prognostic criteria, but not MSKCC classification. VeriStrat showed the potential to further refine current grouping of RCC patients, separating MSKCC intermediate patients into VeriStrat Good and VeriStrat Poor subgroups with statistically significantly different PFS (log-rank p = 0.030).
Heinrich Roder, D.Phil., Chief Technology Officer of Biodesix stated, "This data set shows that our test, VeriStrat, may be helpful in identifying specific and useful disease characteristics in RCC. It is also exciting to see that our test is showing utility across multiple solid tumor